OnkoSight NGS AML Panel

Synonyms

• LAB4138
• ONKOSIGHT NGS AML PANEL

Cerner Name

OnkoSight Advanced NGS Rapid AML Panel

Clinical Info

Tumor sequencing by NGS detecting mutations in 30 genes associated with AML. Mutations often have prognostic significance, may confer 
resistance to FDA approved therapies, or may qualify patients for late-stage clinical trials.

Specimen Sources

Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous Bone Marrow Bone Marrow Aspirate

Specimen Types

Aspirate Blood Bone Marrow

Specimen Volume

Container

Lavender Top Tube

Collection Instructions

Container/Tube: Lavender top tube
Specimen: 2 mL Bone Marrow or Whole Blood
Alternate Specimens: Bone Marrow - Green Top, Peripheral Blood - Lavender Top,
Peripheral Blood - Green Top, Eppendorf tube, Unstained Slide, Formalin-fixed,
Paraffin-embedded Tissue
Decalcified specimens are not recommended for NGS testing.
Note: Please indicate specimen type

Transport Instructions

Room Temperature

Specimen Stability

30 Days Room Temperature or Refrigerated

Methodology

Genotyping by Next Generation Sequencing
Gene:
ASXL1BRAFBCORCEBPACSFR3DDX41DNMT3AETV6EZH2FLT3GATA2HRASIDH1IDH2JAK2KITKMT2AKRASNF1NPM1NRASPDGFRAPHF6PTPN11RUNX1SETBP1STAG2TET2TP53WT

Days Performed

TAT: 10 - 12 Days

Performing Laboratories

GenPath BioReference
Test Code: TL94

CPT

81450

PDM

1659925

Results

Result Interpretation

Forms